BMYBristol Myers Squibb
Bristol-Myers Squibb Company ("we", the "Company", "Bristol Myers Squibb", or "BMS") was incorporated under the laws of the State of Delaware in August 1933 under the name Bristol-Myers Company, as successor to a New York business started in 1887. 10-K, Item 1
- Employees
- 32,500
- Headquarters
- Princeton, NJ
- CEO
- Christopher S. Boerner
- Next results
- around Feb 4, 2027
The numbers BMY said it expected, in its earnings releases of the last 3 years, next to what it then reported for the same period. Each target links to the sentence in the release; each result to the 10-Q or 10-K it was first reported in.
Of 1 range targets with a reported result: 1 came in above the last range given, 0 within it, 0 below it.
| Target | What the company said | Reported | Result |
|---|---|---|---|
| Diluted EPS (company-defined) Fiscal 2026 |
Given $6.05 to $6.35 release 2026-02-05
Kept $6.05 to $6.35 release 2026-04-30
Raised $6.75 to $7.00 release 2026-07-30
Lowered $6.35 to $6.55 release 2026-10-29
|
– | No standard number |
The company's words2026 Non-GAAP1Line-Item Guidance … Diluted EPS $6.05 - $6.35 release 2026-02-05 2026 financial guidance … Non-GAAP EPS range of $6.05 to $6.35, with total revenues and non-GAAP EPS trending toward the upper end of the ranges release 2026-04-30 2026 revenue guidance … Increasing non-GAAP EPS range to $6.75 to $7.00 release 2026-07-30 2026 revenue guidance … Updating non-GAAP EPS range to $6.35 to $6.55, inclusive of a $(0.60) per share net impact from Acquired IPRD charges and licensing income release 2026-10-29 | |||
| Revenue (company-defined) Fiscal 2026 |
Given $46.00B to $47.50B release 2026-02-05
Kept $46.00B to $47.50B release 2026-07-30
Raised $49.00B to $50.00B release 2026-10-29
|
– | No standard number |
The company's words2026 Non-GAAP1Line-Item Guidance … Total Revenues ~ (Reported & Ex-FX) $46.0 - $47.5 billion release 2026-02-05 Non-GAAP1,2Line-Item Guidance April July (Prior) (Updated) … Total Revenues (Reported & Ex-FX) $46.0 - $47.5 billion release 2026-07-30 Non-GAAP1,2Line-Item Guidance July October (Prior) (Updated) … Total Revenues $49.0 - $50.0 billion release 2026-10-29 | |||
| Revenue Fiscal 2026 |
Given $46.00B to $47.50B release 2026-04-30
|
– | Not reported yet |
The company's words2026 financial guidance … with revenues of ~$46.0 billion to $47.5 billion; release 2026-04-30 | |||
| Diluted EPS (company-defined) Fiscal 2025 (ended 2025-12-31) |
Given $6.55 to $6.85 release 2025-02-06
Raised $6.70 to $7.00 release 2025-04-24
Lowered $6.35 to $6.65 release 2025-07-31
Narrowed $6.40 to $6.60 release 2025-10-30
|
– | No standard number |
The company's words2025 Non-GAAP1Line-Item Guidance … Diluted EPS $6.55-$6.85 release 2025-02-06 As a result of these changes, the company is raising the midpoint of its 2025 non-GAAP EPS guidance by $0.15 per share to an expected range of $6.70 to $7.00. release 2025-04-24 2025 revenue guidance … Updating non-GAAP EPS range to $6.35 to $6.65, inclusive of an unfavorable $(0.57) per share impact from the BioNTech Acquired IPRD charge release 2025-07-31 2025 revenue guidance … Updating non-GAAP EPS range to $6.40 to $6.60, inclusive of an $(0.80) per share net impact from Acquired IPRD charges and licensing income release 2025-10-30 | |||
| Revenue Fiscal 2025 (ended 2025-12-31) |
Given $45.80B to $46.80B release 2025-04-24
|
$48.19B 10-K filed 2026-02-11 |
Above the range |
The company's wordsThe company is increasing its full-year revenue guidance from approximately $45.5 billion to a range of approximately $45.8 billion to $46.8 billion, reflecting the strong performance of the Growth Portfolio, better-than-expected Legacy Portfolio sales in the first quarter of 2025, and a favorable impact of approximately $500 million related to foreign exchange rates. release 2025-04-24 | |||
| Revenue (company-defined) Fiscal 2025 (ended 2025-12-31) |
Given $46.50B to $47.50B release 2025-07-31
Raised $47.50B to $48.00B release 2025-10-30
|
– | No standard number |
The company's wordsBristol Myers Squibb is increasing its full-year 2025 non-GAAP revenue guidance from a range of approximately $45.8 billion to $46.8 billion, to a range of approximately $46.5 billion to $47.5 billion, reflecting the strength of the Growth Portfolio, better-than-expected Legacy Portfolio sales in the second quarter, and a favorable impact of approximately $200 million related to foreign exchange rates. release 2025-07-31 Bristol Myers Squibb is increasing its full-year 2025 non-GAAP revenue guidance from a range of approximately $46.5 billion to $47.5 billion, to a range of approximately $47.5 billion to $48.0 billion. release 2025-10-30 | |||
| Diluted EPS (company-defined) Fiscal 2024 (ended 2024-12-31) |
Given $7.10 to $7.40 release 2024-02-02
Kept $7.10 to $7.40 release 2024-04-25
Lowered $0.75 to $0.95 release 2024-10-31
|
– | No standard number |
The company's wordsProvides 2024 Guidance with Revenues Increasing by Low Single-Digits; … Non-GAAP EPS Range $7.10 to $7.40, Excludes Impact of Pending Transactions release 2024-02-02 2024 line-item guidance updates are: … Diluted EPS $7.10 to $7.40 release 2024-04-25 Raising 2024 Revenue Guidance to Approximately +5% (+6% Adjusting for Foreign Exchange), Non-GAAP EPS Range Increased to $0.75 to $0.95 release 2024-10-31 | |||
Targets are read from the sentences of the EX-99 exhibits of 8-K item 2.02 filings (12 releases since 2024-02-02), without AI; in outlook tables only the first column is read. The result compares the reported number with the last range given before the period was reported. Results come from SEC's XBRL company facts, as first reported. A company's target can use its own definition (META's capital expenditures include finance lease payments, for example), so read the quote.
Work on BMY in a spreadsheet:
Excel workbook (a sheet per section, ten years by column, charts, links to the filings) ·
CSV.
For a Google Sheet that stays up to date, paste =IMPORTDATA("https://tickdelta.com/company/BMY/export.csv") into a cell.